A phase 1, single-centre, randomised, double-blind, placebo-controlled, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of intravenous and subcutaneous CSL312 in healthy subjects.

Trial Profile

A phase 1, single-centre, randomised, double-blind, placebo-controlled, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of intravenous and subcutaneous CSL312 in healthy subjects.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs CSL 312 (Primary) ; CSL 312 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions
  • Sponsors CSL
  • Most Recent Events

    • 12 Jul 2017 Status changed from not yet recruiting to active, no longer recruiting.
    • 17 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top